Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
0(0%)
Results Posted
43%(3 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_2
1
9%
Ph phase_1
10
91%

Phase Distribution

10

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
10(90.9%)
Phase 2Efficacy & side effects
1(9.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

63.6%

7 of 11 finished

Non-Completion Rate

36.4%

4 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(7)
Terminated(4)

Detailed Status

Completed7
Withdrawn2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
77.8%
Most Advanced
Phase 2

Trials by Phase

Phase 110 (90.9%)
Phase 21 (9.1%)

Trials by Status

withdrawn218%
completed764%
terminated218%

Recent Activity

0 active trials
Showing 5 of 11
terminatedphase_2

CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy

NCT01902381
completedphase_1

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

NCT02484391
completedphase_1

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

NCT02168140
completedphase_1

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

NCT02232152
completedphase_1

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

NCT01835041
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT01902381Phase 2

CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy

Terminated
NCT02484391Phase 1

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Completed
NCT02168140Phase 1

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Completed
NCT02232152Phase 1

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Completed
NCT01835041Phase 1

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Completed
NCT01766219Phase 1

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

Completed
NCT01839981Phase 1

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed
NCT03370159Phase 1

CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

Withdrawn
NCT01931787Phase 1

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Completed
NCT02472626Phase 1

6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Withdrawn
NCT02168907Phase 1

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Terminated

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11